摘要
This study compared the effects of megestrol acetate (MA) prophylactic (p-MA) versus reactive (r-MA) use for critical body-weight loss (>5% from baseline) during concurrent chemoradiotherapy (CCRT) in patients with advanced pharyngolaryngeal squamous cell carcinoma (PLSCC).
Patients receiving CCRT alone in two phase-II trials were included for analyses. Both the p-MA and r-MA cohorts received the same treatment protocol at the same institution, and the critical body-weight loss, survival, and adverse event profiles were compared.
The mean (SD) weight loss was 5.1% (4.7%) in the p-MA cohort (
= 54) vs. 8.1% (4.6%) in the r-MA cohort (
= 50) (
= .001). The percentage of subjects with body-weight loss >5% was 42.6% in the p-MA cohort vs. 68.0% in the r-MA cohort (
= .011). Tube feeding was needed in 22.2% of p-MA vs. 62.0% of r-MA patients (
< .001). Less neutropenia (26.0% vs. 70.0% [
< .001]) and a shorter duration of grade 3-4 mucositis (2.4 ± 1.4 vs. 3.6 ± 2.0 wk [
= .009]) were observed with p-MA treatment. Disease-specific survival, locoregional control, or distant metastasis-free survival did not differ. Less competing mortality from secondary primary cancer resulted in a better overall survival trend in the p-MA cohort.
p-MA may reduce body-weight loss and improve adverse event profiles during CCRT for patients with PLSCC.